NextCure, Inc. Common Stock

Day range

$5.96 – $6.57

Open

$6.00

Prev close

$6.23

Volume

33.99K

Market cap

$28.53M

Shares out

3.61M

P/E

—

P/S

—

P/B

5.18

P/FCF

—

ROE

-744.5%

ROA

-422.4%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 12, 2026

• Quarterly earningsNov 10, 2026

  On November 10, 2026, NextCure, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.

• Executive compensation changeOct 30, 2026

  In connection with his departure, Dr. Guha entered into a severance agreement and release with the Company (the "Severance Agreement"). In exchange for a release of claims in favor of the Company, the Severance Agreement provides for severance benefits consistent with those provided for a termination without cause under Dr. Guha's existing employment agreement... Subject to and conditioned upon the occurrence of the closing of the Merger, the Severance Agreement provides for additional severance equal to the enhanced severance benefits for a termination without cause in relation to a change in control, as set forth in Dr. Guha's Employment Agreement.

• Stock splitSep 25, 2026

  The Company's board of directors approved a 1:12 split, and the Company filed the 2025 Reverse Split Amendment with the Delaware Secretary of State on July 10, 2025. Upon the effectiveness of the 2025 Reverse Split Amendment, every twelve shares of Common Stock then outstanding were combined and converted into one share of Common Stock.

• Material charge or gainSep 3, 2026

  In connection with the Amendment, the Company paid a one-time termination fee of approximately $0.8 million and forfeited its security deposit of approximately $39,000.

• Private placementJul 14, 2026

  Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the 'Purchase Agreement') with Avere, pursuant to which they have agreed, subject to the terms and conditions of the Purchase Agreement, to purchase (including by contribution of Company Notes (as defined in the Merger Agreement)) immediately prior to the First Effective Time, shares of Avere capital stock and pre-funded warrants to purchase shares of Avere capital stock (together, the 'PIPE Securities') for an aggregate purchase price of approximately $320 million in a private placement (the 'Private Placement').

Days to cover

3.0

Short interest

184.03K

Avg volume

61.91K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
  negativeGlobeNewswire Inc.· Jul 14, 2026
• NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
  neutralGlobeNewswire Inc.· Jul 14, 2026
• What's Going On With NextCure Stock Wednesday?
  neutralBenzinga· Jun 3, 2026
• NextCure Provides Business Update
  neutralGlobeNewswire Inc.· Jan 23, 2026
• NextCure (NXTC) Q2 Loss Widens 71%
  negativeThe Motley Fool· Aug 7, 2025